You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immune-modulatory radiotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC Trial in Switzerland (Durvalumab, Radiotherapy)

Recruiting
  • Non-small Cell Lung Cancer
  • NSCLC
  • Aarau, Switzerland
  • +12 more
Oct 17, 2022

Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies Trial in Chuo-ku (ASP1948)

Completed
  • Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies
  • Chuo-ku, Tokyo, Japan
    Site JP810001
Jan 17, 2023

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8

Not yet recruiting
  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • PD-L1/IDO Peptide Vaccine
  • Pembrolizumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 24, 2023

Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy Trial in Chongqing (Super-hyperfractionation Pulse Radiotherapy)

Recruiting
  • Lung Cancer
  • +2 more
  • Super-hyperfractionation Pulse Radiotherapy
  • Chongqing, Chongqing, China
  • +1 more
Feb 22, 2023

Metastatic Extracranial Malignant Solid Tumor, Radiotherapy, Immune Checkpoint Blockade Trial in Shantou (Intestinal Low Dose

Not yet recruiting
  • Metastatic Extracranial Malignant Solid Neoplasm
  • +3 more
  • Intestinal Low Dose Radiotherapy-1Gy
  • +3 more
  • Shantou, Guangdong, China
    Cancer Hospital, Shantou University Medical College
Oct 7, 2023

Prostate, Lung, Melanoma and Breast Cancer Patients Following

Recruiting
  • Prostate Cancer
  • +3 more
  • SBRT
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

NSCLC Without Mutation in Epidermal Growth Factor Receptor (Disorder) Trial (tereotactic body radiotherapy)

Not yet recruiting
  • Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
  • tereotactic body radiotherapy
  • (no location specified)
Dec 1, 2023

Cervical Cancer, Endometrial Cancer, Uterine Cancer Trial in Belgium (drug, radiation, dietary supplement)

Completed
  • Cervical Cancer
  • +2 more
  • Antwerp, Belgium
  • +3 more
Sep 6, 2021

NSCLC Trial in Amsterdam (Ipilimumab, Cemiplimab, SBRT)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Amsterdam, Noord-Holland, Netherlands
    Antoni van Leeuwenhoek - Netherlands Cancer Institute
Jan 10, 2023

Lung Cancer Stage IV Trial in Maastricht (Radiation)

Not yet recruiting
  • Lung Cancer Stage IV
  • Radiation
  • Maastricht, Netherlands
    Maastricht Radiation Oncology (Maastro)
Aug 29, 2023

NSCLC Stage III Trial (radiotherapy, Platinum-Based Drug, Immunotherapy)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage III
  • radiotherapy
  • +3 more
  • (no location specified)
Sep 10, 2023

SCLC,Extensive Stage Trial in Hangzhou (Thoracic radiotherapy)

Recruiting
  • SCLC,Extensive Stage
  • Thoracic radiotherapy
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 14, 2022

Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic

Not yet recruiting
  • Advanced Solid Tumor
  • +4 more
  • Peking, Beijing, China
    Department of radiation oncology, Peking University Third Hospit
Jun 20, 2023

Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Taoyuan City, Taiwan
    Chang Gung Memorial Hospital at Linkou
Nov 17, 2023

Non Small Cell Lung Cancer Trial in Changsha (radiotherapy, Chemotherapy + immunotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • radiotherapy
  • Chemotherapy + immunotherapy
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Oct 17, 2022

Esophageal Carcinoma Trial (Immune Checkpoint Inhibitors)

Not yet recruiting
  • Esophageal Carcinoma
  • Immune Checkpoint Inhibitors
  • (no location specified)
Jul 6, 2023

Head and Neck Squamous Cell Carcinoma, Hypofractionation, Radiotherapy Trial (HYpofractionated, Dose-redistributed RAdiotherapy

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +4 more
  • HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)
  • conventional fractionated radiotherapy
  • Rotterdam, Zuid Holland, Netherlands
    Erasmus MC
Dec 7, 2022

ors of Immune Response and Local Microbiome

Completed
  • Breast Cancer
  • Prostate Cancer
    • New York, New York
      Weill Cornell Medical College
    Aug 11, 2022

    High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

    Recruiting
    • High-Risk Localized Soft Tissue Sarcoma
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 20, 2023

    Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

    Not yet recruiting
    • Nasopharyngeal Carcinoma
    • +3 more
    • Intensity Modulated Radiation Therapy
    • +3 more
    • (no location specified)
    Jul 11, 2023

    Oligometastatic Disease Trial (IMSA101, Immune checkpoint inhibitor, PULSAR)

    Not yet recruiting
    • Oligometastatic Disease
    • (no location specified)
    May 5, 2023

    Oligoprogressive Trial (IMSA101, Immune checkpoint inhibitor, PULSAR)

    Not yet recruiting
    • Oligoprogressive
    • (no location specified)
    May 5, 2023

    NSCLC, Metastatic Lung Non-Small Cell Carcinoma, Non Small Cell Lung Cancer Trial (Palliative Radiotherapy: 5 x 4Gy, chemo +

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +2 more
    • Palliative Radiotherapy: 5 x 4Gy
    • chemotherapy + immune checkpoint inhibitors
    • (no location specified)
    Jun 27, 2022

    NSCLC, NSCLC Stage IV Trial in Madison (Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Non-small Cell Lung Cancer Stage IV
    • Madison, Wisconsin
      University of Wisconsin Carbone Cancer Center
    Sep 21, 2022

    Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

    Not yet recruiting
    • Advanced Diffuse Large B-Cell Lymphoma
    • +2 more
    • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
    • Radiotherapy beyond standard R-CHOP Chemotherapy
    • (no location specified)
    May 24, 2023